volumes, lower ultrafiltration rates and higher clearance of uremic toxins. Indeed, patients treated with high-dose HD therapies have lower blood pressure [6] [7] [8] , improved serum phosphorus levels [6, 7, 9] , regression of left ventricular mass [6, 7, 10] and improved quality of life [6, 7] . In an observational study, 177 patients on frequent nocturnal home HD had 5-year survival of 85%, similar to survival rates in a matched cadaveric renal transplant cohort [11] .
A substantial barrier to widespread use of high-dose HD therapies is the inability of dialysis centers to accommodate frequent or long-duration HD. Among many other barriers to growth of high-dose home HD is the absence of a smaller, patient-friendly home HD system that delivers high-dose HD [5, 12] . Devices should mitigate inherent risks associated with HD and permit easy and time-saving set up and take down, thus reducing the burden for the patient and care partner.
This report describes the first clinical evaluation of a novel home HD system, VIVIA (Baxter Healthcare Corporation, Deerfield, IL, USA). The two studies discussed herein were performed to evaluate the safety and performance of VIVIA in an in-center environment prior to patient use in the home setting.
M A T E R I A L S A N D M E T H O D S
VIVIA hemodialysis system VIVIA includes the VIVIA Treatment Device and the VIVIA Water Device (Figure 1 ). The VIVIA Treatment Device consists of the patient module (including the VIVIA Dialysate Set and Ultrafilter, the VIVIA Blood Set, the VIVIA Dialyzer, VIVIA Acid and VIVIA Bicarb), the pump module that provides pneumatic pressure to maintain the flow of blood and dialysate and the touchscreen module that serves as the user interface to guide the user from treatment setup through to completion. The VIVIA Treatment Device also generates dialysate, as well as monitors and controls blood and dialysate pathways.
In comparison with conventional HD machines, the VIVIA Treatment Device has a pneumatically controlled diaphragmatic pump. The VIVIA blood flow can be set up to 400 mL/min, in contrast to a setting of up to 650 mL/min in conventional machines. The dialysate flow of conventional devices reaches up to 1000 mL/min, while the VIVIA Treatment Device delivers up to 400 mL/min. VIVIA has been validated to generate in situ dialysate for infusion (for priming, bolus administration and rinseback), avoiding the extra steps needed to set up and use saline bags in conventional devices. Anticoagulant delivery in VIVIA is done through an integrated heparin delivery system in which a new 30 mL (1000 unit/mL) heparin vial is directly installed and seated into the heparin port. This eliminates the need for transfer of heparin to a syringe from a concentrated heparin bottle, dilution in a saline bag and transfer into a syringe that is then installed into a machine syringe pump. For ease of use, VIVIA features extended use of the blood set and dialyzer compared with the single-use requirements for conventional devices. Extended use is achieved through automated in situ nonchemical hot-water disinfection of the blood set and dialyzer. Prior to each treatment, VIVIA performs an automated clearance test of the dialyzer, alerting the user to replace the dialyzer if necessary. An access disconnect sensor is integrated in VIVIA, a feature not found in other HD devices.
VIVIA has built-in protective systems and alarms to ensure safety. Dialysate solution composition is monitored through redundant conductivity cells in the dialysate flow path, with specific alarm set points. Thermistor measurements of the dialysate temperature are done at different points in the device. Volumetric control, adjustment and monitoring of the ultrafiltration rate are regulated closely. Blood leak in the dialyzer is detected by photometric sensors, whereas blood leak to the environment is monitored by fluid leak sensors. Arterial and venous pressures are tightly controlled and measured continuously during treatment. The VIVIA access disconnect sensor, integrated into the blood tubing set, is automatically activated when the patient connects at the start of treatment. When a disconnect in the blood circuit is detected, VIVIA sounds an alarm, the blood pumps stop and the system goes into safe mode. As noted above, VIVIA monitors the clearance of the dialyzer at each treatment and alerts the patient when to change the dialyzer.
The VIVIA Dialyzer is a high-flux polyethersulfone dialyzer with a surface area of 2.1 m 2 . The VIVIA Dialyzer and VIVIA 
Blood Set are validated for multiple use by undergoing in situ automated hot-water disinfection (85 C for 1 h) between treatments. The VIVIA Treatment Device produces dialysate for infusion into the patient during priming, rinseback and for volume expansion during hypotension instead of using saline.
The VIVIA Water Device is designed to supply ultrapure water (via reverse osmosis and electronic deionization) to the VIVIA Treatment Device to generate dialysate flow rates of up to 400 mL/min; however, the Water Device was not used because it was not available at the time of the study. Instead, the Millenium HX Water Portable Dialysis Water System (Mar Cor, Plymouth, MN, USA) was used to produce dialysis water purified by reverse osmosis during these studies. Importantly, the quality of the dialysis water produced by this portable device meets minimum Association for the Advancement of Medical Instrumentation/International Organization for Standardization (AAMI/ISO) water quality standards for dialysis.
Both studies were conducted in accordance with the principles and guidelines set forth in the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice. Written informed consent was obtained from every patient prior to participation in any research activity.
First-in-man clinical study
This was a prospective, open-label, single-arm, nonrandomized study designed to assess the safety and performance of the VIVIA Treatment Device in a supervised setting by trained clinical staff. The study consisted of a 2-week screening period and a 10-week treatment period. Briefly, male and female patients !18 years old were eligible if they were on chronic thriceweekly HD for the last 90 days and achieved a single-pool urea Kt/V (spKt/V) !1.2 (or an equivalent urea reduction ratio of !0.65 or an equilibrated urea Kt/V !1.0 or a weekly standardized Kt/V !2.0) on two occasions within 60 days of enrollment. Exclusion criteria were a history of noncompliance with dialysis therapies, prescheduled living donor kidney transplant within the next 6 months or a severe comorbidity with a life expectancy of <1 year. Patients with known allergic reactions to PUREMA polyethersulfone were also excluded.
During the first 2 weeks, patients were stabilized on their new dialysis prescription. The last 8 weeks of the treatment period were used to evaluate the performance of the VIVIA Treatment Device (evaluable period); however, safety data were collected during the entire 10-week treatment period.
All treatments in this study were performed at two study sites in the USA (Orlando Clinical Research Center, Orlando, FL and DaVita Clinical Research, Minneapolis, MN, USA). Patients were treated for up to 4 h on Monday, Wednesday, Thursday (or Friday) and Saturday. Blood flow rate and treatment time could be adjusted during the first 2 weeks of the treatment period, but these parameters were not changed during the evaluable period to mitigate the influence of these factors on the performance assessment of the VIVIA Dialyzer with multiple use. Heparin administration was individualized to inhibit extracorporeal circuit clotting or fibrin formation yet minimize postdialysis bleeding. Initial heparin dosing was based on the practice in the dialysis clinic. The clinician adjusted the heparin dose during the stabilization period based on the activated partial thromboplastin time (aPTT), with the goal of achieving aPTT ratio between 1.5 and 2.5 times baseline [13, 14] .
A new blood set and dialyzer were used at the beginning of the evaluable period. Before each treatment, dialyzer sodium clearance was measured by the VIVIA Treatment Device and the dialyzer and blood set were reused unless the dialyzer sodium clearance was 90% of the dialyzer initial measurement, there were functional defects of the dialyzer or blood set (leaks, tubing separations) or there were physical appearance abnormalities (such as significant blood clots or biomaterial) present.
All adverse events (AEs) were collected starting from the time the patient signed the informed consent until the end of the study. An AE was considered serious if it resulted in death, hospitalization, prolongation of hospitalization or if it was an important medical event that required an intervention to prevent a death or hospitalization. An AE was considered microbiologically related if it was accompanied by fever, rigors or sepsis during or within 4 h after an HD treatment.
VIVIA Treatment Device performance was determined by assessing dialysis dose and ultrafiltration. Dialysis dose was calculated as weekly standard urea Kt/V (stdKt/V) from spKt/V determined weekly on a Wednesday (preceded by a nontreatment day) [15] [16] [17] . Urea spKt/V was calculated from predialysis and postdialysis serum urea nitrogen concentrations using the second-generation Daugirdas equation [15] then converted to weekly stdKt/V values [17] . Blood samples were taken before and after dialysis as per Kidney Disease Outcomes Quality Initiative (KDQOI) guidelines [18] and processed at a central laboratory (SGS Life Sciences Services, Lincolnshire, IL, USA).
Ultrafiltration was assessed for each HD treatment and was summarized for the 8-week evaluable period. Fluid weight removed was calculated as the total ultrafiltration removed (as recorded by the VIVIA Treatment Device), corrected for the priming and rinseback volumes (as recorded by the VIVIA Treatment Device) and total oral intake and total output (such as emesis and urine). Patient weight was measured before and after each HD treatment using a calibrated digital scale to determine 'weight change'.
Samples (from the venous line) for assessing dialysate quality were taken at the beginning of the 10-week treatment period, after each dialyzer replacement, at a minimum every week, and at the end of the 10-week treatment period. All dialysate samples were assayed for bacteria and endotoxin levels based on a standard [19] at the central laboratory. 
The study consisted of a 2-week screening period and a 6-week treatment period where patients were treated thrice weekly for 6-8 h/treatment. The first week of the treatment period was used to stabilize patients on their new prescriptions. The performance of the VIVIA Treatment Device was assessed during the last 5 weeks (evaluable period).
A new blood set and dialyzer were used at the beginning of the 5-week evaluable period and the conditions for the multiple use of the dialyzer were similar to those used in the first-in-man study. Safety data were collected during the entire 6-week treatment period in a manner similar to that employed during the first study. Definitions for AEs were the same in both studies.
Performance of the VIVIA Treatment Device was also determined by assessment of dialysis dose and ultrafiltration. In this study, however, dialysis dose was calculated as the spKt/V determined at the midweek treatment preceded by 1 nontreatment day using the second-generation Daugirdas equation [15] . Ultrafiltration was assessed for each HD treatment.
Samples for assessing dialysate quality were taken at device installation and before treatments on Days 1, 10 and 18. All dialysate samples were collected and assayed in a similar manner to that used in the first study.
R E S U L T S
Twenty-one patients received treatment with the VIVIA Treatment Device during the first-in-man study; 20 of these patients completed the 10-week treatment period. Seventeen patients were treated during the extended duration study; 16 of these patients completed the 6-week treatment period. Baseline characteristics for study patients are shown in Table 1 .
Combining both studies, 1114 HD treatments were performed with the VIVIA Treatment Device (816 in the first-inman study and 298 in the extended-duration study). Baseline and in-study treatment parameters for both studies are shown in Table 2 . Heparin dose was determined by measuring the aPTT ratio. In the first-in-man study, the mean [6 standard deviation (SD)] aPTT was 2.42 6 0.59 times higher than baseline after initial heparin infusion and 1.64 6 0.45 higher than baseline before the end of treatment. In the extended duration study, the mean (6SD) aPTT was 2.26 6 1.01 times higher than baseline after initial heparin infusion and 2.42 6 1.32 times higher before the end of treatment. Notably, dialysate flow rates were lower during both studies than before study entry and the heparin loading dose and total heparin infusion requirements increased from baseline.
Safety
One hundred and three AEs were reported in the first-inman study and 52 AEs were reported in the extended-duration study, for a combined AE rate of 14 events/100 treatments. Intradialytic hypotension was the most common AE in both studies (2 occurrences/100 treatments in the first-in-man study and 5 occurrences/100 treatments in the extended duration study). Ten AEs were considered device related; nine of these were blood loss (50-250 mL) and occurred primarily during rinseback or toward the end of an HD treatment. The remaining device-related AE was hypotension. Six patients experienced a serious AE (anemia, asthma, fractured ankle, hypotension, pain in an extremity and arteriovenous fistula thrombosis); all of these events resulted in hospitalization, but none were considered related to the VIVIA Treatment Device. No patient experienced a microbiologically related AE and no patient died or was withdrawn from the study due to an AE.
Performance
In the first-in-man study, the mean weekly stdKt/V was 2.97 [95% confidence interval (CI) 2.84-3.11]. In the extended duration study, the mean urea spKt/V was 2.49 (95% CI 2.02-2.96). Figure 2 shows weekly stdKt/V by week for the first-in-man study and urea spKt/V by week for the extended duration study during each study's respective evaluable period. The mean (6SD) ultrafiltration volume for the first-in-man study was 2.77 6 1.26 kg (range À0.4-6.4 kg) and 3.66 6 1.37 kg (range 0.6-7.7 kg) for the extended-duration study [20] . The difference between fluid weight removed (as determined by the VIVIA Treatment Device) and weight change (as measured by a digital calibrated weight scale) is graphically demonstrated in Figure 3 . The correlation between these two measured parameters was strong. The median difference between fluid weight removed and weight change was À0.20 kg for the first-in-man study and À0.30 kg for the extended duration study, indicating a small but consistently greater weight change as measured by the scale than fluid removed.
Dialysate quality
A total of 630 dialysate samples were collected from VIVIA Treatment Devices during these studies. Of these, 626 samples (99%) showed no bacterial growth at 72 h. Two samples (firstin-man clinical study) showed bacterial counts of 0.002 CFU/ mL (1 CFU/500 mL sample). These two samples were taken from nonpatient devices, and the positive results from root cause analysis were likely due to contaminated ice that was used to transport the samples. In the extended-duration study, five endotoxin measurements (0.8%) exceeded the threshold of 0.03 EU/mL (0.
tic techniques were not required; it is plausible that such handling of the device contributed to the elevated endotoxin level. Although a review of the other four out-of-range endotoxin values showed that they were valid as defined by the testing procedure, retesting of all these samples (in quadruplicate) resulted in measured values that were consistent at <0.03 EU/mL.
Extended use of the VIVIA dialyzer
The number of dialyzers used and the maximum use count for patients in both studies are shown in Table 3 . A large variability in the number of times a dialyzer could be reused, both among and within patients, is evident. In both studies, the majority of patients were able to achieve at least 10 uses from the same VIVIA Dialyzer. The most common reason for dialyzer replacement (62% of occurrences in both trials combined) was due to the physical appearance of the dialyzer or blood set, usually small amounts of fibrin seen within the venous header of the VIVIA Dialyzer or the blood pump pods of the blood set. The amount and frequency of fibrin deposition improved with optimization of the heparin prescription. Dialyzers were replaced in 8% of treatments due to failed in situ tests for dialyzer sodium clearance.
D I S C U S S I O N
The vast majority of HD devices obtain market clearance based on predicate comparisons. Clinical studies prior to use in 'real life' are not required by regulatory bodies. In contrast, VIVIA includes unique features that reduce the burden of HD and mitigate inherent risks of HD. Given these differences versus conventional HD devices, the safety and performance of VIVIA were tested in controlled clinical environments.
The majority of AEs observed in these two clinical studies were secondary to underlying comorbidity or the HD therapy itself. No AEs related to the infusion of dialysate were observed. The majority of device-related AEs were secondary to clotting of the extracorporeal blood circuit or incomplete rinsebackevents known to occur with conventional HD devices when anticoagulation is not optimal. Compared with baseline, patients within both clinical studies required an increase in either the heparin loading dose or infusion rate, or both. aPTTs were targeted for 1.5-2.5 times the baseline value for each patient [13, 14] . The increased heparin utilization may have been due to more attention given to anticoagulation during the studies and/or the desire to achieve optimal anticoagulation to maximize use of the same dialyzer and blood set. Despite the increase in heparin use above baseline, no increase in bleeding events was observed.
The performance of VIVIA was determined by measuring urea clearance and ultrafiltration accuracy. Urea clearances in both studies were well above published clinical guidelines [21, 18] and within the expected range. The maximum blood and dialysate flow rate with VIVIA is 400 mL/min, an intentional design feature to limit the size of the pneumatic pumps, noise VIVIA also performed ultrafiltration as desired. The correlation between fluid weight removed and weight change was strong and consistent across both clinical studies. The use of digital calibrated scales and measurement of all fluid input and output allowed us to tease out the amount of insensible fluid loss during HD treatments [22] [23] [24] . Although this varied among patients, the median insensible fluid loss for mean 4-and 7-h treatments was 200 and 300 mL, respectively. Given that each patient's weight did not change throughout both clinical studies, it is unlikely that insensible fluid loss has any clinical relevance in the management of HD patients.
The studies demonstrated the feasibility of extended use of the VIVIA Dialyzer and Blood Set for multiple treatments using nonchemical in situ hot-water disinfection. The majority of patients were able to achieve 10 or more uses from the same VIVIA Dialyzer and Blood Set, a feature that reduces the burden of therapy on the patient and/or care partner. As shown in Table 3 , the variability within and among patients was considerable. Extended use of the same dialyzer and blood set was improved with optimized anticoagulation using the aPTT as a guide [13, 14] .
These studies are not without limitations. Control groups were not used in either study. Although clinical studies are not required for the majority of HD devices prior to their commercial launch, we designed these studies to meet regulatory guidance. The studies were also performed in in-center settings and not the home environment. Although VIVIA is specifically designed for the home, rigorous performance testing is difficult to perform in the home setting, where additional nondevice factors may impact safety and performance. The duration of each study was also too short to determine long-term safety and clinical effectiveness. Future studies are planned to gather these data. It should also be noted that more accurate formulas for calculating stdKt/V for HD therapies applied more frequently than thrice weekly have only recently been published [25, 26] ; however, use of such formulas using data from the first-in-man clinical study resulted in minor differences that would not alter conclusions regarding the ability to achieve an adequate dialysis dose [27] .
In conclusion, data from these two clinical studies conducted in prevalent HD patients confirm the safety and expected performance of VIVIA.
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